Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Standardized Ginkgo biloba leaf extract (EGb 761)

Ginkgo Biloba Extract (EGb 761) · also known as Ginkgo leaf extract, EGb 761, Ginkgo flavonoids, Ginkgolides

Standardized ginkgo leaf extract (EGb 761, containing 24% flavonoid glycosides and 6% terpene lactones) has meta-analysis evidence of a small cognitive benefit in people with mild to moderate dementia. However, large trials using it to prevent dementia in healthy older adults were negative. Evidence for its vascular mechanisms, such as blocking platelet-activating factor, comes mainly from in-vitro studies.

Typical dose: Standardized EGb 761 extract, 120–240 mg/day in 1–2 doses, taken with breakfast and dinner.
Absorption and forms: Choose a standardized extract that has been treated to remove ginkgolic acids, with ginkgolic acid content below 5 ppm. EGb 761 is only one such preparation, and fresh leaves or products that are not properly prepared should not be treated as equivalent to standardized extracts. It can be taken with or without food, and absorption is good.

Clinical uses and human evidence

Anxiety and stress

BeneficialGrade B · Moderate evidence
Studies (1)
  1. Woelk 2007 · J Psychiatr Res · RCT · n=107 — Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial

Age-related cognitive decline

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Gauthier 2014 · Clin Interv Aging · Meta-analysis · n=2684 — Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials
  2. Snitz 2009 · JAMA · RCT · n=3069 — Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial

All-cause mortality risk

No benefitGrade A · Strong evidence
Studies (2)
  1. Kuller 2010 · Circ Cardiovasc Qual Outcomes · RCT · n=3069 — Does Ginkgo biloba reduce the risk of cardiovascular events?
  2. Vellas 2012 · Lancet Neurol · RCT · n=2854 — Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial

Heart attack, stroke and other cardiovascular events

No benefitGrade A · Strong evidence
Studies (3)
  1. Kuller 2010 · Circ Cardiovasc Qual Outcomes · RCT · n=3069 — Does Ginkgo biloba reduce the risk of cardiovascular events?
  2. Vellas 2012 · Lancet Neurol · RCT · n=2854 — Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial
  3. Dodge 2008 · Neurology · RCT · n=118 — A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline

Memory

No benefitGrade B · Moderate evidence
Studies (2)
  1. Solomon 2002 · JAMA · RCT · n=230 — Ginkgo for memory enhancement: a randomized controlled trial
  2. Snitz 2009 · JAMA · RCT · n=3069 — Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial

Attention and focus

No benefitGrade B · Moderate evidence
Studies (2)
  1. Solomon 2002 · JAMA · RCT · n=230 — Ginkgo for memory enhancement: a randomized controlled trial
  2. Tiemtad 2026 · Phytomedicine · Meta-analysis · n=2107 — Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis

Mechanisms of action

Endothelial nitric oxide synthase (eNOS) coupling and NO vasodilation

★★★☆☆Mechanism evidence: grade CSecondary target

In cells, EGb 761 can enhance eNOS signaling, and in rats it produces a blood pressure-lowering effect that depends on nitric oxide. Changes in human blood flow or vasodilation cannot by themselves prove that eNOS is activated, and the specific mechanisms in the basilar artery of the brain and in the arterioles of the inner ear are not yet established.

References (1)
  1. Koltermann 2007 · Cell and rat study: EGb 761 increased eNOS signaling in cells and produced nitric oxide-dependent blood pressure lowering in rats.

Platelet-activating factor (PAF) antagonism and improved microcirculatory rheology

★☆☆☆☆Mechanism evidence: grade DSecondary target

Ginkgolides can antagonize platelet-activating factor (PAF) in vitro and inhibit the platelet aggregation it induces. However, at standard EGb 761 doses, peak blood levels after oral dosing are far below the concentrations needed in vitro, so results from high-dose pure ginkgolides cannot be directly extrapolated.

References (2)
  1. Koch 2005 · In-vitro human platelet study with pharmacokinetic comparison: the IC50 of a single ginkgolide for inhibiting PAF-induced aggregation was more than roughly 100 times the peak concentration after a standard oral dose of EGb 761.
  2. 1987 study · 6-person crossover trial: 80–120 mg of a ginkgolide mixture inhibited PAF responses, but this ginkgolide dose was far above the amount in standard EGb 761.

Direct free radical trapping and chemical quenching

★☆☆☆☆Mechanism evidence: grade DSecondary target

Ginkgo flavonoids and their components have antioxidant activity in vitro, and after oral intake they exist as metabolites and conjugates. There are no reliable human studies on whether usual doses can directly scavenge free radicals in brain microvessels, and changes in oxidative markers cannot be used to infer this effect directly.

References (2)
  1. 2025 study · Cell and animal study: the proanthocyanidin fraction of EGb 761 showed antioxidant activity in vitro, and metabolites were detected in blood.
  2. Literature search · No direct studies found: no reliable human study was found that directly shows usual doses chemically scavenging free radicals in brain microvessels.

Safety and drug interactions

For people about to have major surgery, and for people taking anticoagulants (such as warfarin) or antiplatelet drugs (such as aspirin or clopidogrel), when to stop ginkgo should be judged against their bleeding risk and the specific procedure. Stopping 2 weeks beforehand can serve as a reference point, but the exact timing must be decided by a doctor. Fresh ginkgo leaves that have not been detoxified are quite toxic and should not be steeped to make a homemade tea.

Additive bleeding risk

Case reports of bleeding events. Each of these has a mild antiplatelet or fibrinolytic effect. Alone, the effect is usually small, but when several are combined, the tendency to bleed becomes more noticeable. Stop them 1–2 weeks before surgery or a tooth extraction, and watch for gum bleeding or more bruising.

With SSRIs, SNRIs and other serotonergic drugs Needs attention

Sertraline, fluoxetine, paroxetine, venlafaxine, duloxetine, tramadol, triptans (migraine drugs)

SSRIs and SNRIs on their own mildly increase the tendency to bleed, and bleeding events have been reported when they are taken with ginkgo. Causality is uncertain, so watch for gum bleeding, bruising and similar signs when the two are combined.

With Antiepileptic drugs High risk

Phenytoin, carbamazepine, phenobarbital, valproate, oxcarbazepine

There are reports of seizures returning in people with well-controlled epilepsy after taking ginkgo, involving drugs such as valproic acid and phenytoin. The reason is not fully clear. People taking anticonvulsants are best off avoiding ginkgo.

Open in the interactive app ›